UNCY

Unicycive Therapeutics Stock Analysis

AI Rating

Good
  • Quality8/10
  • Growth↓ 4/10
  • Value↓ 4/10
Unicycive Therapeutics sales and earnings growth
UNCY Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 53.12%
  • FCF Y/Y↓ -12.68%
Unicycive Therapeutics gross and profit margin trends
UNCY Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 481.33%
Unicycive Therapeutics net debt vs free cash flow
UNCY Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -530.3

Unicycive Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗